Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Director | June 05, 2026 | June 15, 2026 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | July 25, 2017 | July 25, 2017 |
| Moderna, Inc.MRNA · Entity 2025 | Director | April 29, 2020 | April 30, 2020 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | June 22, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcturus Therapeutics Holdings Inc.
Report date June 05, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2036-06-05 | Direct | 15,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 15,000 · Balance 15,000 F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
Intellia Therapeutics, Inc.
Report date July 25, 2017 · Filed July 25, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.91 · Expires 2027-07-24 | Direct | 38,000 |
Reported balance
After 2017-07-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-07-25 · Grant · Acquired 38,000 · Balance 38,000 F1: This option was granted on July 25, 2017 with respect to 38,000 shares of Common Stock, with 33% vesting on July 25, 2018 and the remaining 67% vesting in eight substantially equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on July 25, 2017 with respect to 38,000 shares of Common Stock, with 33% vesting on July 25, 2018 and the remaining 67% vesting in eight substantially equal quarterly installments thereafter.
Moderna, Inc.
Report date April 29, 2020 · Filed April 30, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.37 · Expires 2030-04-29 | Direct | 18,270 |
Reported balance
After 2020-04-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-04-29 · Grant · Acquired 18,270 · Balance 18,270 F1: This option will become fully vested and exercisable on the earlier of April 29, 2021, or the next Annual Meeting of Stockholders, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will become fully vested and exercisable on the earlier of April 29, 2021, or the next Annual Meeting of Stockholders, subject to the recipient's continued service.
Vaxcyte, Inc.
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.11 · Expires 2036-06-22 | Direct | 26,061 |
Reported balance
After 2026-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 26,061 · Balance 26,061 F1: Option shall vest over 36 months, 1/3 of which will vest on June 17, 2027 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option shall vest over 36 months, 1/3 of which will vest on June 17, 2027 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2026 Filed Jun 23, 2026 20:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 26,061 | $0.00 Strike: $52.11 | $0.00 |
DisclosureSEC source: 0001712369-26-000008 · wk-form4_1782246596.xml · derivative · entry 1 Slaoui Moncef · CIK 0001712369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,061 Underlying: Common Stock · 26,061 shares Expires 2036-06-22 F1 · derivative.exercise_date: Option shall vest over 36 months, 1/3 of which will vest on June 17, 2027 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| June 05, 2026 Filed Jun 15, 2026 21:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001193805-26-000825 · e66580_4-slaoui.xml · derivative · entry 1 Slaoui Moncef · CIK 0001712369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-06-05 F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| June 09, 2025 Filed Jun 12, 2025 00:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $12.54 | $0.00 |
DisclosureSEC source: 0001193805-25-000877 · e664623_4-slaoui.xml · derivative · entry 1 Slaoui Moncef · CIK 0001712369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-09 F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| June 19, 2024 Filed Jun 22, 2024 01:30 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 14,794 | $0.00 Strike: $25.96 | $0.00 |
DisclosureSEC source: 0001193805-24-000836 · e663735_4-jing.xml · derivative · entry 2 Slaoui Moncef · CIK 0001712369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,794 Underlying: Common Stock · 14,794 shares Expires 2034-06-19 F2 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the annual grant to the Reporting Person as a member of the Board, prorated based on the date the Reporting Person was appointed to the Board. Read SEC document |
| June 19, 2024 Filed Jun 22, 2024 01:30 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $25.96 | $0.00 |
DisclosureSEC source: 0001193805-24-000836 · e663735_4-jing.xml · derivative · entry 1 Slaoui Moncef · CIK 0001712369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: Shares underlying the option vest monthly over a two year period from the date of grant. This represents the initial grant to the Reporting Person as a member of the Board of Directors. Read SEC document |
| April 29, 2020 Filed Apr 30, 2020 21:31 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 18,270 | $0.00 Strike: $46.37 | $0.00 |
DisclosureSEC source: 0001127602-20-014877 · form4.xml · derivative · entry 1 Slaoui Moncef · CIK 0001712369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,270 Underlying: Common Stock · 18,270 shares Expires 2030-04-29 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 29, 2021, or the next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 54,660 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001127602-19-023029 · form4.xml · derivative · entry 1 Slaoui Moncef · CIK 0001712369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,660 Underlying: Common Stock · 54,660 shares Expires 2029-06-27 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of June 27, 2020, or the next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| July 25, 2017 Filed Jul 25, 2017 20:47 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 38,000 | $0.00 Strike: $16.91 | $0.00 |
DisclosureSEC source: 0001209191-17-046188 · doc4.xml · derivative · entry 1 Slaoui Moncef · CIK 0001712369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2027-07-24 F1 · derivative.exercise_date: This option was granted on July 25, 2017 with respect to 38,000 shares of Common Stock, with 33% vesting on July 25, 2018 and the remaining 67% vesting in eight substantially equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.